Cost–effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Therapy for lupus nephritis (LN) requires treatment with immunosuppressive regimens, often including intravenous cyclophosphamide (IVCY), mycophenolate mofetil (MMF) or azathioprine. Additionally, tacrolimus (original form or generic) is recommended to treat LN patients in Asia, including China. However, the cost–effectiveness of tacrolimus therapy has not previously been assessed. We aimed to estimate the cost–effectiveness of tacrolimus in the treatment of moderate-to-severe LN versus standard therapies in China. Materials & methods: This cost–effectiveness model combined a decision-tree/Markov-model structure to map transitions between health states during induction and maintenance treatment phases. Induction with tacrolimus, IVCY or MMF, was followed by tacrolimus, MMF or azathioprine maintenance. Results: According to the model, during induction, complete remission rates were higher with tacrolimus versus IVCY (relative risk 1.40 vs IVCY [deterministic sensitivity analysis minimum 0.92, maximum 2.13]) and time to response was shorter. Relapse rates were lower with tacrolimus versus azathioprine or MMF during maintenance. Tacrolimus induction and maintenance was the most cost-effective regimen, incurring the lowest total costs (CN¥180,448) with the highest quality-adjusted life-years. Conclusion: The model demonstrated that tacrolimus use in both induction and maintenance therapy may be an efficacious and cost-effective treatment for LN in China.
Supplementary Material
File (suppl_file.docx)
- Download
- 87.29 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
La Paglia GMC, Leone MC, Lepri G et al. One year in review 2017: systemic lupus erythematosus. Clin. Exp. Rheumatol. 35, 551–561 (2017).
2.
Bernatsky S, Boivin J-F, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550–2557 (2006).
3.
Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update. Arthritis Res. Ther. 13, 240 (2011).
4.
Yap DYH, Chan TM. Treatment of lupus nephritis: practical issues in Asian countries. Int. J. Rheum. Dis. 18, 138–145 (2015).
5.
Mok CC. Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese. Lupus. 20, 767–771 (2011).
6.
Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771–1782 (2012).
7.
Zhao W, Zhang L, Han S et al. Cost analysis of living donor kidney transplantation in China: a single-center experience. Ann. Transplant. 17, 5–10 (2012).
8.
Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol. Dial. Transplant. 27, 3248–3254 (2012).
9.
Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann. Rheum. Dis. 62, 435–439 (2003).
10.
Fiehn C. Early diagnosis and treatment in lupus nephritis: how we can influence the risk for terminal renal failure. J. Rheumatol. 33, 1464–1466 (2006).
11.
Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934–3940 (2004).
12.
Hahn BH, McMahon MA, Wilkinson A et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64, 797–808 (2012).
13.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl. 2, 139–274 (2012).
14.
Moya FB, Pineda Galindo LF, García de la Peña M. Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with systemic lupus erythematosus. J. Clin. Rheumatol. 22, 8–12 (2016).
15.
Lightstone L, Doria A, Wilson H, Ward FL, Larosa M, Bargman JM. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun. Rev. 17, 4–10 (2018).
• Review article highlighting that the side effects associated with corticosteroid treatment for lupus nephritis might be minimized by tapering corticosteroids in patients achieving a stable renal remission.
16.
Chinese Nephrotic Syndrome Immunosuppression Treatment Committee. Expert consensus on adult nephrotic syndrome immunosuppressive therapy. Chin. J. Nephrol. 30, 467–474 (2014).
17.
Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat. Rev. Nephrol. 11, 46–61 (2015).
•• Review of evidence supporting the standard of care immunosuppressive treatments, including the use of calcineurin inhibitors, and emerging therapies for the treatment of severe lupus nephritis.
18.
Mok CC, Yap DY, Navarra SV et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology 19, 11–20 (2014).
19.
Chen Y, Sun J, Zou K, Yang Y, Liu G. Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses. Rheumatol. Int. 37, 1089–1099 (2017).
•• Systematic review of the treatment options for lupus nephritis, including the role of tacrolimus as induction therapy.
20.
Palmer SC, Tunnicliffe DJ, Singh-Grewal D et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am. J. Kidney Dis. 70, 324–336 (2017).
21.
Borrows R, Loucaidou M, Van Tromp J et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am. J. Transplant. 4, 1845–1851 (2004).
22.
Li X, Li H, Chen J et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol. Dial. Transplant. 23, 1919–1925 (2008).
• Prospective, open-label cohort study demonstrating that 24 weeks of tacrolimus therapy was effective and steroid-sparing for Chinese adults with steroid dependent minimal change nephrotic syndrome.
23.
Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 68, 813–817 (2005).
24.
Yap DYH, Ma MKM, Mok MMY, Kwan LPY, Chan GCW, Chan TM. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology 53, 2232–2237 (2014).
25.
Chen W, Tang X, Liu Q et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am. J. Kidney Dis. 57, 235–244 (2011).
26.
Singh JA, Hossain A, Kotb A, Wells GA. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Syst. Rev. 5, 155 (2016).
• Systematic review and network meta-analysis of trials of immunosuppressive drugs and corticosteroids in patients with lupus nephritis.
27.
Mok CC, Ying KY, Yim CW et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 75, 30–36 (2016).
•• Randomized, controlled, parallel-group study demonstrating non-inferiority of tacrolimus to mycophenolate mofetil, when combined with prednisolone, for induction therapy of active lupus nephritis.
28.
Webster P, Wardle A, Bramham K, Webster L, Nelson-Piercy C, Lightstone L. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 23, 1192–1196 (2014).
29.
Kraaij T, Bredewold OW, Trompet S et al. TAC-TIC use of tacrolimus-based regimens in lupus nephritis. Lupus Sci. Med. 3, e000169 (2016).
30.
Clarke AE, Panopalis P, Petri M et al. SLE patients with renal damage incur higher health care costs. Rheumatology 47, 329–333 (2008).
31.
Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65, 521–530 (2004).
32.
Chen W, Liu Q, Chen W et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus. 21, 944–952 (2012).
33.
Mohara A, Pérez Velasco R, Praditsitthikorn N, Avihingsanon Y, Teerawattananon Y. A cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Rheumatology 53, 138–144 (2014).
34.
Nee R, Rivera I, Little DJ, Yuan CM, Abbott KC. Cost-utility analysis of mycophenolate mofetil versus azathioprine based regimens for maintenance therapy of proliferative lupus nephritis. Int. J. Nephrol. 2015, 917567 (2015).
35.
Wilson ECF, Jayne DRW, Dellow E, Fordham RJ. The cost–effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology 46, 1096–1101 (2007).
36.
Li X, Ren H, Zhang Q et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol. Dial. Transplant. 27, 1467–1472 (2012).
37.
Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18–26 (2015).
38.
Wang J, Hu W, Xie H et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus. 16, 707–712 (2007).
39.
Bao H, Liu Z-H, Xie H-L, Hu W-X, Zhang H-T, Li L-S. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J. Am. Soc. Nephrol. 19, 2001–2010 (2008).
40.
Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
41.
El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin. Exp. Nephrol. 14, 214–221 (2010).
42.
Feng X, Gu F, Chen W et al. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis. Chin. Med. J. 127, 3718–3723 (2014).
43.
Rathi M, Goyal A, Jaryal A et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 89, 235–242 (2016).
44.
Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70, 732–742 (2006).
45.
Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20, 901–911 (2009).
46.
Kiefer C, Sturtz S, Bender R. Indirect comparisons and network meta-analyses estimation of effects in the absence of head-to-head trials – part 22 of a series on evaluation of scientific publications. Dtsch. Arztebl. Int. 112, 803–808 (2015).
47.
Chan TM, Tse KC, Tang CSO, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14, 265–272 (2005).
48.
Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886–1895 (2011).
49.
Takeuchi T, Wakasugi N. Long-term safety and efficacy of tacrolimus for lupus nephritis patients in real-world setting – results from 5 year interim analysis of post marketing surveillance of 1376 patients in Japan [presentation]. In: American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting, (2015). Abstract 1795.
•• Five-year interim analysis of post-marketing surveillance data demonstrating that tacrolimus therapy was generally tolerable and effective for the treatment of lupus nephritis in Japan.
50.
Zhang X, Liu S, Li Y, Wang Y, Tian M, Liu G. Long-term effectiveness and cost–effectiveness of metformin combined with liraglutide or exenatide for type 2 diabetes mellitus based on the CORE diabetes model study. PLoS ONE 11, e0156393 (2016).
51.
WHO. Global Health Observatory data repository. Life tables by country China. http://apps.who.int/gho/data/?theme=main&vid=60340
52.
Bavanandan S, Yap Y-C, Ahmad G, Wong H-S, Azmi S, Goh A. The cost and utility of renal transplantation in Malaysia. Transplant. Direct. 1, e45 (2015).
53.
Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr. Res. 71, 155–165 (2004).
54.
Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R. Cost–effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J. Med. Econ. 15(Suppl. 1), 3–14 (2012).
55.
Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual. Life Outcomes. 6, 84 (2008).
56.
Tsuchiya T, Fukuda T, Furuiye M, Kawabuchi K. Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer 74, 521–528 (2011).
57.
Sonnenberg FA, Burkman RT, Hagerty CG, Speroff L, Speroff T. Costs and net health effects of contraceptive methods. Contraception 69, 447–459 (2004).
58.
Kidney Service China. Kidney dialysis in China (2019). http://www.kidneyservicechina.com/dialysis-kidney-disease/2686.html
59.
Xiaoming P, Heli X, Chenguang D, Hua L, Guozhen C, Tianci B. Cost of two different therapies for end-stage renal disease in northwest China. J. Med. Coll. PLA 27, 80–86 (2012).
60.
Mo X, Gai Tobe R, Wang L et al. Cost–effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect. Dis. 17, 502 (2017).
61.
Shao H, Zhai S, Zou D et al. Cost–effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr. Med. Res. Opin. 33, 359–369 (2017).
62.
Ayoub I, Nelson J, Rovin BH. Induction therapy for lupus nephritis: the highlights. Curr. Rheumatol. Rep. 20, 60 (2018).
63.
Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69, 2083–2089 (2010).
64.
Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull. World Health Organ. 93, 118–124 (2015).
65.
Bertram MY, Lauer JA, De Joncheere K et al. Cost–effectiveness thresholds: pros and cons. Bull. World Health Organ. 94, 925–930 (2016).
Information & Authors
Information
Published In
Pages: 1125 - 1141
PubMed: 31580156
Copyright
© 2019 Hongsi Jiang. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 16 October 2018
Accepted: 8 August 2019
Published online: 3 October 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Cost–effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0111
Export citation
Select the citation format you wish to export for this article or chapter.